CRISPR THERAPEUTICS AG (CRSP) Operating margin 2016–2025
CRISPR THERAPEUTICS AG (CRSP) operating margin by fiscal year — reported operating income divided by reported revenue.
-18933.6%FY2025 · since FY2016: -1319.3% → -18933.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -18933.6% | -17683.3 pp |
| FY2024 | -1250.4% | -1190.4 pp |
| FY2023 | -60.0% | +56130.5 pp |
| FY2022 | -56190.4% | -56231.2 pp |
| FY2021 | 40.8% | +49336.4 pp |
| FY2020 | -49295.5% | -49311.7 pp |
| FY2019 | 16.1% | +5103.9 pp |
| FY2018 | -5087.8% | -4930.1 pp |
| FY2017 | -157.7% | +1161.6 pp |
| FY2016 | -1319.3% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More CRSP financial trends
CRSP RevenueCRSP Net incomeCRSP Net marginCRSP Gross profitCRSP Gross marginCRSP Operating incomeCRSP Operating cash flowCRSP Free cash flowCRSP Capital expendituresCRSP Return on equityCRSP Stock buybacksCRSP Dividends paidCRSP Total assetsCRSP Total liabilitiesCRSP Shareholders’ equityCRSP overview →